Previous close | 24.76 |
Open | 24.59 |
Bid | 24.41 x N/A |
Ask | 24.42 x N/A |
Day's range | 24.31 - 24.73 |
52-week range | 17.33 - 27.58 |
Volume | |
Avg. volume | 1,787,885 |
Market cap | 9.915B |
Beta (5Y monthly) | -0.28 |
PE ratio (TTM) | 30.51 |
EPS (TTM) | 0.80 |
Earnings date | N/A |
Forward dividend & yield | 0.16 (0.65%) |
Ex-dividend date | 22 May 2023 |
1y target est | 31.00 |
Aurisco Pharmaceutical has good reasons to celebrate. On its 25th anniversary, the high-tech pharmaceutical company dedicated to innovation has received its first Marketing Authorization Approval in China for AUXITON®, the oral finished dosage form of Dydrogesterone, from China's Health Authority, the NMPA. Aurisco is the only company holding both an active USDMF and a valid CEP – the Certificate of compliance with the European Pharmacopoeia, issued by the EDQM for the drug substance.